It has previously been shown that PD patient monocytes have impaired phagocytic capabilities and reduced ability to clear Asyn [61, 62], therefore modulation of CB2 may lead to a therapeutic gain-of-function involving immune cell uptake and clearance. This evidence concerns the gene CNR2 and Parkinson disease.